In this study, we leveraged the anti-tumor properties of the p53 protein to investigate and compare the effectiveness of ARRDC1–p53 (ARP)-sEVs and CD63–p53 (CDP)-sEVs. The gene discussed is CD63; the disease is neoplasm.